We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.
Increased funding is needed to eliminate malaria across 22 Asia-Pacific countries and save an estimated 400,000 lives, according to research published in a new collection of studies on Wellcome Open Research.
On 6-7 May in Zanzibar, Tanzania, the final investigators’ meeting of the Development of Triple Artemisinin-based Combination Therapies (DeTACT) project brought together 35 investigators from participating institutions in Bangladesh, Cambodia, Guinea, Nigeria, Niger, Tanzania, The Gambia, Rwanda, Singapore, and MORU, along with key partners from Fosun Pharma, Medicines for Malaria Venture (MMV), the WHO Global Malaria Programme, and the UK Foreign, Commonwealth and Development Office (FCDO), which funded the project over the past seven years.
